Yuqin Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuqin Song has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Dengju Li
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
66 shared publications - Hang Su
Department of Lymphoma, The Fifth Medical Center of the People's Liberation Army General Hospital, Beijing, China
66 shared publications - Hui Zhou
23Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China
66 shared publications - Xiuhua Sun
14Department of Lymphoma and Head and Neck Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
66 shared publications - Zengjun Li
Department of Lymphoma, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, China
66 shared publications - Zhen Cai
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
66 shared publications
Latest Publications
- 10 October 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (6)
Peripheral CD4 + T‐Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor–Associated Immune Modulation in B‐Cell Lymphoma
Bispecific antibodies (BsAbs) targeting CD20 × CD3 have achieved remarkable efficacy in relapsed or refractory (R/R) B‐cell lymphoma, yet clinical responses remain heterogeneous and predictive biomarkers are lacking. We retrospectively evaluated associations between peripheral immune profiles and outcomes in 40 patients treated with CD20 × CD3 BsAbs and explored BTK inhibitor–associated immune changes using a paired BTK inhibitor cohort, functional assays, mouse models, and single‐cell RNA sequencing. Higher baseline CD4 + T‐cell counts correlated with superior response rates and prolonged progression‐free survival, whereas CD8 + counts showed no association. Elevated CD4 + T‐cell levels were linked to increased activation of effector CD8 + CD28 + T cells and greater induction of IL‐2 and IFN‐γ following treatment. Across paired clinical samples and experimental models, BTK inhibition was associated with CD4 + T‐cell expansion and enhanced T/NK‐cell proliferative and cytotoxic signatures. In an exploratory real‐world observation, three patients received BTK inhibition before glofitamab; all achieved complete responses, with two remaining in remission at data cutoff and one relapsing after 8.4 months. These findings identify peripheral CD4 + T‐cell reserve as a potential biomarker associated with BsAb outcomes and provide a rationale for further investigation of BTK inhibitor–mediated immune modulation in BsAb treatment strategies.
- 10 October 2026
- Published by Wiley in Hematological Oncology
- Vol. 44 (6)
Peripheral CD4 + T‐Cell Reserve as a Potential Biomarker of CD20 × CD3 Bispecific Antibody Outcomes and BTK Inhibitor–Associated Immune Modulation in B‐Cell Lymphoma
Bispecific antibodies (BsAbs) targeting CD20 × CD3 have achieved remarkable efficacy in relapsed or refractory (R/R) B‐cell lymphoma, yet clinical responses remain heterogeneous and predictive biomarkers are lacking. We retrospectively evaluated associations between peripheral immune profiles and outcomes in 40 patients treated with CD20 × CD3 BsAbs and explored BTK inhibitor–associated immune changes using a paired BTK inhibitor cohort, functional assays, mouse models, and single‐cell RNA sequencing. Higher baseline CD4 + T‐cell counts correlated with superior response rates and prolonged progression‐free survival, whereas CD8 + counts showed no association. Elevated CD4 + T‐cell levels were linked to increased activation of effector CD8 + CD28 + T cells and greater induction of IL‐2 and IFN‐γ following treatment. Across paired clinical samples and experimental models, BTK inhibition was associated with CD4 + T‐cell expansion and enhanced T/NK‐cell proliferative and cytotoxic signatures. In an exploratory real‐world observation, three patients received BTK inhibition before glofitamab; all achieved complete responses, with two remaining in remission at data cutoff and one relapsing after 8.4 months. These findings identify peripheral CD4 + T‐cell reserve as a potential biomarker associated with BsAb outcomes and provide a rationale for further investigation of BTK inhibitor–mediated immune modulation in BsAb treatment strategies.
- 25 August 2026
- Published by American Society of Hematology in Blood
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas
Despite advances in the molecular characterization of mature T and NK cell lymphomas, outcomes for these patients is poor especially those with relapsed/refractory (R/R) disease. These tumors possess mutations that often result in tonic T cell receptor (TCR) signaling and an immunosuppressive tumor microenvironment. Interleukin-2-inducible T cell kinase (ITK) plays an important role in TCR signaling and T cell differentiation. Soquelitinib is a covalent oral selective ITK inhibitor that blocks Th2 differentiation while sparing Th1 cells (Th1 skewing). We conducted a phase 1 trial with soquelitinib for the treatment of R/R peripheral T cell lymphomas to determine safety, target occupancy and antitumor activity. A dose escalation design was followed by an expansion cohort to confirm dosing and identify predictive characteristics. Seventy-five patients were enrolled. No dose-limiting toxicities were observed with doses up to 600mg BID and target occupancy exceeding 80% was established for 200mg BID dose. At the 200mg BID dose, number of prior lines of therapy was found to affect antitumor activity as durable complete and partial responses were seen in 37% patients with 1-3 prior therapies; no responses were seen in patients with >3. Objective and durable tumor responses were observed in various histologic subtypes. Blood and tumor biopsies indicated that soquelitinib treatment leads to Th1 skewing, reduction of T cell exhaustion and blockade of Th2 cells. These studies demonstrate soquelitinib is active in T cell lymphomas with a mechanism related to effects on malignant T cells and/or normal T effector cells. Trial registration: NCT03952078 at www.ClinicalTrials.gov.
- 25 August 2026
- Published by American Society of Hematology in Blood
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas
Despite advances in the molecular characterization of mature T and NK cell lymphomas, outcomes for these patients is poor especially those with relapsed/refractory (R/R) disease. These tumors possess mutations that often result in tonic T cell receptor (TCR) signaling and an immunosuppressive tumor microenvironment. Interleukin-2-inducible T cell kinase (ITK) plays an important role in TCR signaling and T cell differentiation. Soquelitinib is a covalent oral selective ITK inhibitor that blocks Th2 differentiation while sparing Th1 cells (Th1 skewing). We conducted a phase 1 trial with soquelitinib for the treatment of R/R peripheral T cell lymphomas to determine safety, target occupancy and antitumor activity. A dose escalation design was followed by an expansion cohort to confirm dosing and identify predictive characteristics. Seventy-five patients were enrolled. No dose-limiting toxicities were observed with doses up to 600mg BID and target occupancy exceeding 80% was established for 200mg BID dose. At the 200mg BID dose, number of prior lines of therapy was found to affect antitumor activity as durable complete and partial responses were seen in 37% patients with 1-3 prior therapies; no responses were seen in patients with >3. Objective and durable tumor responses were observed in various histologic subtypes. Blood and tumor biopsies indicated that soquelitinib treatment leads to Th1 skewing, reduction of T cell exhaustion and blockade of Th2 cells. These studies demonstrate soquelitinib is active in T cell lymphomas with a mechanism related to effects on malignant T cells and/or normal T effector cells. Trial registration: NCT03952078 at www.ClinicalTrials.gov.
- Open Access
- 13 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (S3) , 3-5
Current Treatment Landscape and Advances in Lymphoma in China: A Special Issue
- 13 August 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (S3) , 3-5
Open AccessCurrent Treatment Landscape and Advances in Lymphoma in China: A Special Issue
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2233-2243
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor
PURPOSE: Mantle cell lymphoma (MCL) is a rare and typically aggressive B-cell non-Hodgkin lymphoma characterized by recurrent relapse after short remissions. Sonrotoclax (BGB-11417) is a next-generation B-cell lymphoma 2 inhibitor with greater selectivity and potency than venetoclax, a shorter half-life, and no drug accumulation. Sonrotoclax monotherapy was evaluated in Bruton tyrosine kinase inhibitor–pretreated patients with relapsed/refractory (R/R) MCL. METHODS: BGB-11417-201 (ClinicalTrials.gov identifier: NCT05471843 ) is an ongoing global, open-label, phase I/II trial. Sonrotoclax was orally administered once daily with gradual, 4-week ramp-up to 160 mg or 320 mg to mitigate tumor lysis syndrome (TLS). The primary end point was overall response rate by the independent review committee (ORR-IRC) per Lugano classification; secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Overall, 125 patients were enrolled and assigned to receive sonrotoclax 160 mg (n = 10) or 320 mg (n = 115) target doses once daily. Most patients had advanced disease (stage IV, 78.3%) and were heavily pretreated (median prior therapies, 3). In efficacy-evaluable patients (n = 103), the ORR-IRC was 52.4% (95% CI, 42.4 to 62.4), a statistically significant increase versus the historic control ORR (30%; P < .0001); the complete response rate was 15.5%. Responses were seen across high-risk subgroups, including patients with TP53 mutation (59.1%). With a median study follow-up of 14.2 months, the median DOR-IRC was 15.8 months, and the median PFS-IRC was 6.5 months. Median OS was not reached. The most common all-grade/grade ≥3 treatment-emergent adverse events were neutropenia (35.7%/19.1%), thrombocytopenia (24.3%/9.6%), and anemia (24.3%/7.8%). TLS occurred in 7.0% of patients; all cases resolved without sequelae. CONCLUSION: Sonrotoclax demonstrated rapid, durable responses and manageable safety in heavily pretreated patients with R/R MCL, including high-risk subgroups, supporting its further clinical evaluation as an oral therapy for R/R MCL.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (23) , 2233-2243
Open AccessPhase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor
PURPOSE: Mantle cell lymphoma (MCL) is a rare and typically aggressive B-cell non-Hodgkin lymphoma characterized by recurrent relapse after short remissions. Sonrotoclax (BGB-11417) is a next-generation B-cell lymphoma 2 inhibitor with greater selectivity and potency than venetoclax, a shorter half-life, and no drug accumulation. Sonrotoclax monotherapy was evaluated in Bruton tyrosine kinase inhibitor–pretreated patients with relapsed/refractory (R/R) MCL. METHODS: BGB-11417-201 (ClinicalTrials.gov identifier: NCT05471843 ) is an ongoing global, open-label, phase I/II trial. Sonrotoclax was orally administered once daily with gradual, 4-week ramp-up to 160 mg or 320 mg to mitigate tumor lysis syndrome (TLS). The primary end point was overall response rate by the independent review committee (ORR-IRC) per Lugano classification; secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Overall, 125 patients were enrolled and assigned to receive sonrotoclax 160 mg (n = 10) or 320 mg (n = 115) target doses once daily. Most patients had advanced disease (stage IV, 78.3%) and were heavily pretreated (median prior therapies, 3). In efficacy-evaluable patients (n = 103), the ORR-IRC was 52.4% (95% CI, 42.4 to 62.4), a statistically significant increase versus the historic control ORR (30%; P < .0001); the complete response rate was 15.5%. Responses were seen across high-risk subgroups, including patients with TP53 mutation (59.1%). With a median study follow-up of 14.2 months, the median DOR-IRC was 15.8 months, and the median PFS-IRC was 6.5 months. Median OS was not reached. The most common all-grade/grade ≥3 treatment-emergent adverse events were neutropenia (35.7%/19.1%), thrombocytopenia (24.3%/9.6%), and anemia (24.3%/7.8%). TLS occurred in 7.0% of patients; all cases resolved without sequelae. CONCLUSION: Sonrotoclax demonstrated rapid, durable responses and manageable safety in heavily pretreated patients with R/R MCL, including high-risk subgroups, supporting its further clinical evaluation as an oral therapy for R/R MCL.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (1) , e2400435
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model–Based Cost-Effectiveness Analysis
PURPOSE: Combined-modality therapy (CMT) improves survival in patients with early-stage extranodal natural killer-/T-cell lymphoma (ENKTCL) compared with radiotherapy (RT) alone. However, the effect is inadequate for low-risk patients as defined by nomogram-revised risk index (NRI). As such, it remains unclear whether the survival benefits outweigh the additional costs. MATERIALS AND METHODS: A Markov model was constructed to compare CMT versus RT alone for patients with early-stage ENKTCL, according to five risk groups defined by NRI model. Transition probabilities, effectiveness, and cost data were derived from the China Lymphoma Collaborative Group cohort, while health utility data were estimated from adverse effects. Life-years, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios were calculated from the perspective of Chinese payers. Evaluations for customized countries or settings can be accomplished using a web-based tool. RESULTS: Over the 6-year horizon, CMT increased life-years by 5.47, 5.19, 4.82, 4.62, and 4.49 years at $517,472 US dollars (USD)/QALY, $22,871 USD/QALY, $7,865 USD/QALY, $4,598 USD/QALY, and $2,278 USD/QALY for the low-risk (NRI = 0), intermediate-low-risk (NRI = 1), intermediate-high-risk (NRI = 2), high-risk (NRI = 3), and very high-risk (NRI = 4) groups, respectively. The probabilities of cost-effectiveness at a willingness-to-pay threshold of $5,208 USD/QALY were 0.00%, 0.01%, 7.40%, 72.07%, and 99.10% for each risk group. Over the lifetime horizon, all risk groups, except for low-risk group, had a probability of over 90% of being cost-effective. Estimates were varied according to country settings, integrated through a web-based customized analysis. CONCLUSION: CMT is unlikely to be cost-effective for low-risk patients but highly likely to be cost-effective for high-risk and very high-risk patients. As for intermediate-low or intermediate-high-risk patients, the cost-effectiveness of CMT varies depending on the time horizon and willingness-to-pay threshold.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (1) , e2400435
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model–Based Cost-Effectiveness Analysis
PURPOSE: Combined-modality therapy (CMT) improves survival in patients with early-stage extranodal natural killer-/T-cell lymphoma (ENKTCL) compared with radiotherapy (RT) alone. However, the effect is inadequate for low-risk patients as defined by nomogram-revised risk index (NRI). As such, it remains unclear whether the survival benefits outweigh the additional costs. MATERIALS AND METHODS: A Markov model was constructed to compare CMT versus RT alone for patients with early-stage ENKTCL, according to five risk groups defined by NRI model. Transition probabilities, effectiveness, and cost data were derived from the China Lymphoma Collaborative Group cohort, while health utility data were estimated from adverse effects. Life-years, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios were calculated from the perspective of Chinese payers. Evaluations for customized countries or settings can be accomplished using a web-based tool. RESULTS: Over the 6-year horizon, CMT increased life-years by 5.47, 5.19, 4.82, 4.62, and 4.49 years at $517,472 US dollars (USD)/QALY, $22,871 USD/QALY, $7,865 USD/QALY, $4,598 USD/QALY, and $2,278 USD/QALY for the low-risk (NRI = 0), intermediate-low-risk (NRI = 1), intermediate-high-risk (NRI = 2), high-risk (NRI = 3), and very high-risk (NRI = 4) groups, respectively. The probabilities of cost-effectiveness at a willingness-to-pay threshold of $5,208 USD/QALY were 0.00%, 0.01%, 7.40%, 72.07%, and 99.10% for each risk group. Over the lifetime horizon, all risk groups, except for low-risk group, had a probability of over 90% of being cost-effective. Estimates were varied according to country settings, integrated through a web-based customized analysis. CONCLUSION: CMT is unlikely to be cost-effective for low-risk patients but highly likely to be cost-effective for high-risk and very high-risk patients. As for intermediate-low or intermediate-high-risk patients, the cost-effectiveness of CMT varies depending on the time horizon and willingness-to-pay threshold.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Comparison of PI3K inhibitor toxicities and their efficacies for relapsed and/or refractory indolent lymphoma treatments
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Comparison of PI3K inhibitor toxicities and their efficacies for relapsed and/or refractory indolent lymphoma treatments
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
List of participating hospitals for the clinical trial NCT04370405
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
List of participating hospitals for the clinical trial NCT04370405
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Detailed inclusion and exclusion criteria for the clinical trial (NCT04370405)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Detailed inclusion and exclusion criteria for the clinical trial (NCT04370405)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Representativeness of Study Participants
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Investigator-assessed response outcomes (FAS)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Investigator-assessed response outcomes (FAS)